Document 0691
 DOCN  M94A0691
 TI    Zidovudine-resistant HIV-1 in primary infection.
 DT    9412
 AU    Imrie A; Hurren L; Cunningham P; Vizzard J; Carr A; Gurusinghe A; Deacon
       N; Penny R; Cooper DA; Centre for Immunology, St Vincents's Hospital.
 SO    Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:36 (abstract no. SC4).
       Unique Identifier : AIDSLINE ASHM5/94348964
 AB    AIM: To assess the prevalence of transmitted zidovudine-resistant HIV in
       individuals who seroconverted after 1990. METHODS: HIV was isolated from
       10 homosexual men with symptomatic primary HIV infection, and from their
       sexual partners when possible. Isolates obtained within the first two
       months following onset of symptoms were assessed for ZDV sensitivity
       with a PBL assay. HIV RT from one donor-recipient pair was sequenced.
       RESULTS: Isolates obtained within a mean of 16.5 (r8-32) days of onset
       of symptoms demonstrated a mean ZDV IC50 of 0.008 (r0.001-0.041); IC50
       of isolates from 3 sexual partners ranged from 0.001 to 0.08. Sequence
       analysis of the HIV RT of one donor-recipient pair with IC50 values of
       0.08 and 0.01 respectively showed a mutation at position 70 (Lys-Arg) in
       the donor RT; the RT of his sexual partner showed a wild-type sequence.
       CONCLUSION: HIV with reduced sensitivity to ZDV was isolated from a
       homosexual man, but not from his seroconverting sexual partner.
       Phenotypic and genotypic analysis of additional PHI isolates and
       donor-recipient pairs will be presented.
 DE    Adult  Drug Resistance, Microbial/GENETICS  Homosexuality  Human  HIV
       Seropositivity/*DRUG THERAPY/MICROBIOLOGY  HIV-1/*DRUG EFFECTS/GENETICS
       Male  Mutation  Reverse Transcriptase/ANTAGONISTS & INHIB/GENETICS
       Sexual Partners  Zidovudine/*THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).